Cantor Fitzgerald Believes Collegium Pharmaceutical (NASDAQ: COLL) Won't ... - Analyst Ratings

Analyst Ratings
Cantor Fitzgerald Believes Collegium Pharmaceutical (NASDAQ: COLL) Won't ...
Analyst Ratings
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) today and set a price target of $40. The company's shares opened today at $26.93, close to its 52-week high of $29.90. Folkes noted:.en meer »